Trevena, Inc.
Trevena, Inc. develops and commercializes medicines for central nervous system disorders. Lead product candidates include OLINVYK for moderate-to-severe acute pain and TRV734 for moderate-to-severe acute and chronic pain. TRV045 is a novel S1P modulator for managing chronic pain.
Overview
Strengths
- Consistent growth: revenue has compounded at 365.4% a year over 3 years, rising in 2 of them.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 39.3% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 5 years.
- Unstable profitability: operating margin ranged from -85,394% to -961% over the last 4 years, with operating losses in 4 of them.
Key Financial Data